Research article on FZ002 was published in Science Translational Medicine

November 6, 2020

Our first-in-class yeast based immunotherapy for C. diff infection was recently published in the Science Translational Medicine. The novelty and great potential of our platform and product have been reported by Science magazine, BioTechScope and MedicalExpress etc.